Gufic Biosciences granted patent for Tigecycline; stock climbs 2%

Gufic was trading at Rs118.85 per piece up by Rs2.05 or 1.76% from its previous closing on the BSE, at around 12.42pm.

Dec 01, 2020 12:12 IST India Infoline News Service

Gufic Biosciences Limited informed the exchanges on Saturday that it has been granted a patent for Tigecycline by the Eurasian Patent Office. EAPO granted the company the patent for its invention of "A Freeze Dired Parenteral Composition of Tigecycline and process for preparation thereof".

The company added that Tigecycline is a tetracycline antibioti¢wmedication used for a number of bacterial infections and is used to treat certain serious infections including community acquired pneumonia (a lung infection that developed in a persan who was not in the hospital), skin infections, and infections of the abdomen.

Further, EAPO member States are Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russian Federation, Tajikistan and Turkmenistan. 

Gufic was trading at Rs118.85 per piece up by Rs2.05 or 1.76% from its previous closing on the BSE, at around 12.42pm.

Related Story